Organon's Implanon Contraceptive Gets Second "Approvable" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requests more information from Organon on its implantable contraceptive Implanon following receipt of a second "approvable" letter. The company also awaits FTC clearance of a marketing and distribution agreement with Merck KGaA subsidiary Laboratoire Théramex for an oral contraceptive.